Wedbush Has Bullish Estimate for PepGen FY2028 Earnings

PepGen Inc. (NASDAQ:PEPG) – Analysts at Wedbush upped their FY2028 earnings per share (EPS) estimates for PepGen in a research report issued on Monday, December 16th. Wedbush analyst L. Chico now forecasts that the company will earn ($1.85) per share for the year, up from their previous estimate of ($2.08). Wedbush has a “Outperform” rating and a $12.00 price target on the stock. The consensus estimate for PepGen’s current full-year earnings is ($2.84) per share.

Several other equities research analysts have also recently issued reports on PEPG. Bank of America cut shares of PepGen from a “neutral” rating to an “underperform” rating and set a $3.00 target price on the stock. in a research report on Monday. HC Wainwright reiterated a “buy” rating and issued a $26.00 price target on shares of PepGen in a report on Friday, November 8th.

PepGen Trading Up 1.0 %

PEPG traded up $0.04 during midday trading on Thursday, hitting $4.10. The company’s stock had a trading volume of 10,858 shares, compared to its average volume of 131,647. PepGen has a 52-week low of $2.90 and a 52-week high of $19.30. The firm has a 50-day moving average price of $6.15 and a two-hundred day moving average price of $10.47. The firm has a market cap of $133.64 million, a P/E ratio of -1.38 and a beta of 1.56.

Institutional Trading of PepGen

Institutional investors and hedge funds have recently bought and sold shares of the business. Point72 DIFC Ltd purchased a new stake in PepGen during the second quarter worth approximately $42,000. American Century Companies Inc. boosted its position in PepGen by 19.9% during the 2nd quarter. American Century Companies Inc. now owns 20,028 shares of the company’s stock worth $320,000 after purchasing an additional 3,326 shares during the period. Rhumbline Advisers boosted its position in PepGen by 36.1% during the 2nd quarter. Rhumbline Advisers now owns 18,853 shares of the company’s stock worth $301,000 after purchasing an additional 5,002 shares during the period. Jane Street Group LLC increased its holdings in PepGen by 29.1% in the 3rd quarter. Jane Street Group LLC now owns 27,748 shares of the company’s stock valued at $237,000 after purchasing an additional 6,254 shares in the last quarter. Finally, Allspring Global Investments Holdings LLC purchased a new position in PepGen in the third quarter valued at about $95,000. Institutional investors and hedge funds own 58.01% of the company’s stock.

PepGen Company Profile

PepGen Inc, a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. Its lead product candidate is PGN-EDO51, an EDO peptide that is in Phase 2 clinical trial to treat Duchenne muscular dystrophy (DMD) patients.